Andersen Global Continues West African Expansion with Addition of Tax and Legal Firm in Benin
30.7.2020 16:30:00 EEST | Business Wire | Press release
Andersen Global announces its entrance into Cotonou, Benin with the addition of collaborating firm Fiduciaire Conseil and Assistance (FCA), a full-service tax and legal firm founded 20 years ago.
The firm, led by Managing Partner Sybel Akuesson, combines a strong, balanced tax and legal practice whose staff of 17 professionals provides assistance in labor law and corporate law as well as offers full tax capabilities to businesses involved in a variety of industries.
“In an increasingly complex world, the African market has begun demanding a new pace and scale of doing business, especially when it comes to the demand of legal services,” Sybel said. “In the spirit of stewardship, we are always looking for ways to grow and improve as a firm, and our collaboration with Andersen Global ensures we can meet all of our clients’ tax and legal needs globally in a seamless manner.”
“Sybel and his team share our organization’s commitment to independence and transparency,” said Andersen Global Chairman and Andersen CEO Mark Vorsatz. “Teaming with like-minded individuals positions us to provide even more comprehensive, best-in-class solutions to our clients and adds breadth and depth to our presence in Africa, particularly West Africa. They currently have pre-existing relationships with several of our collaborating firms in West Africa, which is invaluable and allows us to maintain the competitive edge in the region. We have nearly completed our build out in West Africa and are now the largest firm in the region as well as on the continent.”
Andersen Global is an international association of legally separate, independent member firms comprised of tax and legal professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 6,000 professionals worldwide and a presence in over 184 locations through its member firms and collaborating firms.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005219/en/
Contact information
Megan Tsuei
Andersen Global
415-764-2700
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 13:01:00 EEST | Press release
TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA AI models and tools to further enhance capabilities across advanced reasoning, autonomous analysis and video intelligence. The integration allows TACTICAAI to draw on NVIDIA’s AI ecosystem while maintaini
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 13:01:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has
Bregal Milestone Backs Nethive With Majority Growth Investment and JoyComm Acquisition22.10.2026 11:00:00 EEST | Press release
Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in Nethive S.p.A. (“Nethive” or the “Company”), a leading Italian cybersecurity services and software provider. Alongside its investment in Nethive, Bregal Milestone has also backed Nethive’s acquisition of IT security specialist Joy Comm S.r.l. (“JoyComm”). Founded in 2014 by Alessandro Bellato and Diego Rocco, Nethive has become a trusted cybersecurity partner to blue-chip enterprises, SMEs, and public-sector organizations across Italy. Its platform spans managed security services, professional services and technology resale, helping organizations protect critical infrastructure and networks, strengthen cyber resilience and reduce operational complexity. Nethive combines deep technical expertise with 24/7 monitoring, threat detection and response, risk and vulnerability management, infrastructure protection and specialist consultancy. The Company serves more than 250
EOS and VOP CZ Sign Memorandum of Understanding to Explore Cooperation on Czech Programmes22.10.2026 10:00:00 EEST | Press release
EOS Defence Systems (EOS) and VOP CZ have signed a Memorandum of Understanding (MoU) at Future Forces Forum in Prague to explore cooperation on wheeled armoured vehicle programmes for the Czech Army and other future defence projects in the Czech Republic and Europe where VOP CZ is involved. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021408045/en/ EOS and VOP CZ sign a Memorandum of Understanding at Future Forces Forum in Prague. Left to right: Martin van de Voorde, Sales Director Europe, EOS; Vlastimil Navrátil, Managing Director, VOP CZ; Pavla Ungrová, Sales Director, VOP CZ; Rear Admiral Richard Caton, Australia’s Military Representative to NATO and the EU; Group Captain Michael Schleeman, Australia’s Defence Attaché; and Matej Pupák, Program Lead, VOP CZ. The agreement brings together EOS' expertise in advanced remote weapon systems (RWS) with VOP CZ's established capabilities in military vehicle integration, produ
Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease22.10.2026 10:00:00 EEST | Press release
Ferreri and Prilenia Therapeutics B.V.today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, with Canada to follow. Designed to evaluate the efficacy and safety of pridopidine (administered as an oral capsule twice a day), and to generate data for regulatory evaluation, the global, approximately 400-participant, randomized, double-blind, placebo-controlled PRECISE-HD study will assess the clinical effect of the investigational treatment on disease progression, functional capacity, motor function, cognition, speech and quality of life. “The initiation of PRECISE-HD in Europe marks a milestone for the Huntington’s disease research community. This confirmatory Phase 3 study has been designed to bu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom